制酸剂的全球市场:现状分析与预测(2022年～2028年)

全球制酸剂的市场规模在2022年～2028年间预计将以年复合成长率约9％成长。市场的增长归因于老年人口的扩大、胃食管反流病（GERD）（如糜烂性食管炎、巴雷特食管和食管癌）的发病率增加，以及消费者对胃肠道健康的认识。

本报告提供全球制酸剂市场相关调查分析，提供市场规模与预测分析，主要趋势和机会，企业简介等资讯。

目录

第1章 市场简介

第2章 调查手法·前提条件

第3章 市场摘要

第4章 摘要整理

第5章 全球制酸剂市场COVID-19影响

第6章 全球制酸剂市场收益(2020年～2028年)

第7章 市场考察:各医药品分类

• 质子帮浦阻断剂
• H2拮抗剂
• 酸中和剂
• 其他

第8章 市场考察:各剂型

• 锭剂
• 胶囊
• 悬浮液
• 滴液
• 其他

第9章 市场考察:各流通管道

• 医院药局
• 零售药局
• 线上药局
• 其他

第10章 市场考察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他的北美
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他的欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 其他的亚太地区
• 其他地区

第11章 制酸剂的市场动态

• 推动市场要素
• 市场课题
• 影响的分析

第12章 制酸剂市场机会

第13章 制酸剂市场趋势

第14章 政策和法规架构

第15章 供需分析

• 需求端分析
• 供应端分析

第16章 价值链分析

第17章 竞争模式

• 竞争情形
  • 波特的五力分析

第18章 企业概要

• GlaxoSmithKline plc.
• Pfizer Inc.
• Bayer AG
• Dr. Reddy's Laboratories Ltd.
• AstraZeneca PLC.
• Boehringer Ingelheim GmbH
• Sun Pharmaceuticals Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Abbott Laboratories
• Johnson & Johnson

第19章 免责声明

The global antacids market is experiencing significant growth due to the increasing aging population and Gastroesophageal Reflux Disease (GERD), such as erosive esophagitis, Barrett esophagus, and esophageal cancer amongst the population, and awareness regarding gastrointestinal health among consumers. For Instance, In March 2020, Lupin launched the authorized generic for Horizon Therapeutics PLC's Vimovo (naproxen/esomeprazole magnesium) delayed-release tablets in the United States. The product is a combination of naproxen, and esomeprazole magnesium, in which naproxen is used for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers. Furthermore, PLC's Vimovo is used when quick relief of your symptoms is required. Therefore, the market for antacids is expected to witness a significant CAGR of 9% during the forecast period.

Global Antacids Market is expected to register a CAGR of around 9% over the period of 2022-2028. This is mainly due to the growing geriatric population suffering from Gastroesophageal Reflux Disease (GERD), which occurs due to higher incidences of acidity, that results in the side effects of drugs like non-steroidal, anti-inflammatory drugs., and stringent government regulations coupled with the growing focus of major stakeholders in the healthcare industry to adopt to make antacids products more sustainable with fewer side effects and cost-effective. Major healthcare companies are investing heavily in their products due to rising social awareness regarding gastrointestinal cases, and other associated disorders, such as erosive esophagitis, Barrett esophagus, and esophageal cancer. According to World Gastroenterology Organization, the prevalence of GERD is increasing worldwide and ranges from nearly 2.5% to 6.6% in Eastern Asia and nearly 13.8% to 25.8% in North America. This rise in the prevalence of these disorders is contributing to market growth. Furthermore, many therapies are used for the treatment and the use of antacids significantly rises in such cases which is responsible for excessive use of antacids and also significantly contributes to the market for antacids. Therefore, the market for antacids is expected to witness significant growth during the forecast period.

GlaxoSmithKline plc., Pfizer Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., AstraZeneca PLC., Boehringer Ingelheim GmbH, Sun Pharmaceuticals Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Johnson & Johnson are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst Drug Class, proton pump inhibitors category accounted for the majority share in the market in 2020"

Based on drug class, the market is classified into proton pump inhibitors, H2 antagonists, acid neutralizers and others. Amongst types, the proton pump inhibitors category accounted for a significant share of the market. This is mainly due to its use in the treatment of gastroesophageal reflux disease (also known as GERD). This class is considered standard antacids and this type of drug reduce stomach acid production significantly and for a long time. This segment's dominance is attributable to the presence of a large number of proton pump inhibitor antacids in the global market.

"Amongst Formulation, tablets are expected to witness highest CAGR during the forecast period"

Based on formulation, the market is categorized into tablets, capsules, suspension, drops, and others. Among these, the tablet is expected to witness the highest CAGR during the forecast period. This is mainly due to the strong prevalence of the presence of a variety of chewable tablets in the market with different flavors that help to improve patient adherence to the medication. Furthermore, supportive government initiatives to create awareness regarding the treatment options for gastric issues are expected to well for the adoption of innovative drugs. The continuous development of the new products and procedures is likely to strengthen the market of the segment during the forecast period.

"North America to witness significant growth during the forecast period"

North America is expected to show the highest CAGR growth in the antacids market. The major contributors to the growth of this market are US and Canada. The increase in technology development in emerging economies, as well as the expansion of the healthcare industry, has contributed to the growth of the North America market. North America has a higher adoption rate of medical treatment and antacid drugs. The enhanced awareness regarding the availability of various antacids has propelled the growth of the market in the region. Hence these require drugs in the region which drives the demand for antacids in the region. Furthermore, increasing geriatric population and new product launches, and various developmental strategies adopted by the regional market will drive market growth. Furthermore, according to the Centers for Disease Control and Prevention (CDC) 2018 statistics, the total number of adults diagnosed with ulcers in the United States was found to be 14.8 million. The number of populations with ulcers is proportional to the population suffering from GERD. Furthermore, the biopharmaceutical companies and diagnostics industry owing to the presence of well-established market players and frequent product launches in the region.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

Global antacids market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Antacids Market
• 2.2. Research Methodology of the Antacids Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ANTACIDS MARKET COVID-19 IMPACT

6 GLOBAL ANTACIDS MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY DRUG CLASS

• 7.1. Proton pump inhibitors
• 7.2. H2 antagonist
• 7.3. Acid neutralizers
• 7.4. Others

8 MARKET INSIGHTS BY FORMULATION

• 8.1. Tablets
• 8.2. Capsules
• 8.3. Suspension
• 8.4. Drops
• 8.5. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Online Pharmacies
• 9.4. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. UK
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Australia
  • 10.3.5. Rest of Asia-Pacific
• 10.4. Rest of World

11 ANTACIDS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 ANTACIDS MARKET OPPORTUNITIES

13 ANTACIDS MARKET TRENDS

14 POLICY & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

• 18.1. GlaxoSmithKline plc.
• 18.2. Pfizer Inc.
• 18.3. Bayer AG
• 18.4. Dr. Reddy's Laboratories Ltd.
• 18.5. AstraZeneca PLC.
• 18.6. Boehringer Ingelheim GmbH
• 18.7. Sun Pharmaceuticals Industries Ltd.
• 18.8. Takeda Pharmaceutical Company Limited
• 18.9. Abbott Laboratories
• 18.10. Johnson & Johnson

19 DISCLAIMER